Sign In
Buy NVS
$148.93
+1.85 (+1.26%)
At Close: Jun 22, 2026
Here's 14 Top Dividends On Earth At Ideal Prices For October
07:03am, Saturday, 09'th Oct 2021
Kiplinger "insights for investors" online first offered a list of 91 "Top Dividend Stocks From Around The World" 7/13/20. Two Kiplinger articles provided this 102 Top Dividend Stocks list 7/1/21. 39 E
3 No-Brainer High-Yield Dividend Aristocrat Buys During This Market Slide
12:58am, Thursday, 30'th Sep 2021
3 No-Brainer High-Yield Dividend Aristocrat Buys During This Market Slide
Novartis Posts New Data Reinforcing Efficacy, Convenience Of Cosentyx Autoinjector In Psoriasis
09:28am, Wednesday, 29'th Sep 2021
Novartis AG (NYSE: NVS) announced data from an international Phase 3b study of Cosentyx (secukinumab) in plaque psoriasis. Data showed that treatment with Cosentyx 300 mg in a 2 mL autoinjector (Un
This Potential Indication Could Be a Winner for Novartis
06:55am, Wednesday, 29'th Sep 2021
The U.S. Food and Drug Administration accepted Novartis' filing for tislelizumab to treat esophageal cancer.
7 Biotech Stocks Entering the Golden Boom Phase
03:30pm, Tuesday, 28'th Sep 2021
These biotech stocks offer a more mature take on an otherwise risky sector. These companies already have successes under their belt.
5 European Dividend Aristocrats Offer Huge Income and Growth Potential
07:27am, Monday, 27'th Sep 2021
With September and the third quarter almost over, many investors are looking to the fourth quarter and beyond.
Novartis Adds Vision Loss Gene Therapy Program Via Arctos Acquisition
07:07am, Tuesday, 21'st Sep 2021
Novartis AG (NYSE: NVS) has acquired Arctos Medical, adding a preclinical optogenetics-based AAV gene therapy program and Arctos' proprietary technology to its ophthalmology portfolio. Deal terms
Novartis buys gene therapy company Arctos Medical
01:36am, Tuesday, 21'st Sep 2021
Novartis has bought gene therapy specialist Arctos Medical to boost its efforts finding treatments for patients with severe vision loss, the Swiss company said on Tuesday.
Why Did Deutsche Bank Downgrade This Big Pharma Stock?
02:29pm, Monday, 20'th Sep 2021
Deutsche Bank has downgraded Novartis AG (NYSE: NVS) to Sell from Hold with a price target of CHF 70, down from CHF 80. Analyst Emmanuel Papadakis sees "grounds for outright caution near term
Novartis' Prostate Cancer Therapy Linked To Improved Quality Of Life
06:51am, Friday, 17'th Sep 2021
Novartis AG (NYSE: NVS) is building the case for its radioligand therapy, 177Lu-PSMA-617. With positive Phase 3 primary endpoint data in the bag, Novartis at the European Society of Medical Oncology
14 High-Yield Blue Chips For A Rich Retirement
05:13am, Tuesday, 14'th Sep 2021
14 High-Yield Blue Chips For A Rich Retirement
A Look at R&D Spending in Pharma
05:13pm, Sunday, 12'th Sep 2021
In GAAP accounting, fixed assets are usually capitalized on a company's balance sheet and subsequently amortized over their expected useful life.
The 13 Ideally Priced Most Reliable Dividends On Earth For September
11:52pm, Wednesday, 08'th Sep 2021
The 13 Ideally Priced Most Reliable Dividends On Earth For September
3 International Stocks to Buy for Dividend Growth
12:55pm, Wednesday, 08'th Sep 2021
International stocks tend to offer higher yields than their U.S.-based counterparts, and also offer geographic diversification. The post 3 International Stocks to Buy for Dividend Growth appeared firs
Novartis Stops Iscalimab Trial In Kidney Transplant Patients
07:09am, Friday, 03'rd Sep 2021
Novartis AG (NYSE: NVS) has halted a Phase 2 trial of CFZ533 (iscalimab) in kidney transplant patients. The decision follows interim data that showed iscalimab was not as good as tacrolimus-based t
